Condensed Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities
Net loss	$ (11,307)	$ (9,129)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	14	4
Stock-based compensation expense	1,390	618
Amortization of premiums and accretion of discounts on marketable securities, net	(334)	216
Amortization of right-of-use asset	38	33
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(899)	1,416
Other assets	(44)	(65)
Accounts payable	(878)	121
Accrued clinical trial expenses	2,486	281
Operating lease liability	(38)	(32)
Accrued expenses and other current liabilities	(603)	(1,762)
Net cash used in operating activities	(10,175)	(8,299)
Cash flows from investing activities
Purchases of marketable securities	(52,131)	(9,090)
Proceeds from maturities and sales of marketable securities	10,204	4,000
Purchases of property and equipment	0	(9)
Net cash used in investing activities	(41,927)	(5,099)
Net change in cash and cash equivalents	(52,102)	(13,398)
Cash and cash equivalents at the beginning of the period	130,101	122,162
Cash and cash equivalents at the end of the period	77,999	108,764
Supplemental disclosure of noncash investing activities
Purchase of property and equipment in accounts payable	$ 0	$ 10